Evidence map›Paper›PMID 23278719›Full record

ArticleImmunology2013

Chemokine programming dendritic cell antigen response: part I - select chemokine programming of antigen uptake even after maturation.

Jaehyung Park, Cindy T Wu, James D Bryers

Open access · greenAbstract read
In one paragraph

Article in Immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. HIV-1-Infected CD4Journal of immunology (Baltimore, Md. : 1950) · 2022
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jaehyung ParkDepartment of Bioengineering, University of Washington, Seattle, WA 98195, USA.
Cindy T Wu
James D Bryers
University of Washington · US

Funding

Periodontal Biomaterials with BITE (Biofilm Immunity with Tissue Engineering)R01DE018701 · NIDCR · UNIVERSITY OF WASHINGTON · PI BRYERS, JAMES D. · 2008 to 2019
$5.0M
Biomaterials that Promote Infection ImmunityR01AI074661 · NIAID · UNIVERSITY OF WASHINGTON · PI BRYERS, JAMES D. · 2008 to 2012
$2.5M
Biomaterials that Promote Infection ImmunityR56AI074661 · NIAID · UNIVERSITY OF WASHINGTON · PI BRYERS, JAMES D. · 2015 to 2015
$400k
NIAID NIH HHS R01 AI074661NIAID NIH HHS R01AI074661NIAID NIH HHS R56 AI074661NIDCR NIH HHS R01 DE018701NIDCR NIH HHS R01DE018701
6 · The paper itself

Abstract

Here, we report on the successful programming of dendritic cells (DCs) using selectively applied mixtures of chemokines as a novel protocol for engineering vaccine efficiency. Antigen internalization by DCs is a pivotal step in antigen uptake/presentation for bridging innate and adaptive immunity and in exogenous gene delivery used in vaccine strategies. Contrary to most approaches to improve vaccine efficiency, active enhancement of antigen internalization by DCs as a vaccine strategy has been less studied because DCs naturally down-regulate antigen internalization upon maturation. Whereas chemokines are mainly known as signal proteins that induce leucocyte chemotaxis, very little research has been carried out to identify any additional effects of chemokines on DCs following maturation. Here, immature DCs are pre-treated with select chemokines before intentional maturation using lipopolysaccharide (LPS). When pre-treated with a mixture of CCL3 and CCL19 in a 7 : 3 ratio, then matured with LPS, chemokine pre-treated DCs exhibited 36% higher antigen uptake capacity than immature DCs and 27% higher antigen-processing capacity than immature DCs treated only with LPS. Further, CCL3 : CCL19 (7 : 3) pre-treatment of DCs modulated MHC molecule expression and secretion of various cytokines of DCs. Collectively, DC programming was feasible using a specific chemokine combination and these results provide a novel strategy for enhancing DC-based vaccine efficiency. In Part II, we report on the phenotype changes and antigen presentation capacity of chemokine pre-treated murine bone marrow-derived DCs examined in long-term co-culture with antigen-specific CD4(+) T cells.

Indexed as

AnimalsAntigen PresentationCell LineChemokine CCL19Chemokine CCL3Dendritic CellsMiceVaccinesCcl19 protein, mouseCcl3 protein, mouseChemokine CCL19Chemokine CCL3Vaccines

Identifiers

PMID23278719
PMCPMC3634540
OpenAlexW2003054328

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.